Metodebevisregister

Bioequivalence Analysis

Bioequivalence Analysis is a regulatory-grade statistical framework used to determine whether a test drug formulation (generic or reformulated) delivers the active ingredient to the systemic circulation at a rate and extent comparable to a reference product. Introduced by Donald J. Schuirmann in 1987, the method operationalizes equivalence through the Two One-Sided Tests (TOST) procedure, replacing the ambiguous absence-of-difference paradigm with an explicit equivalence margin evaluated on log-transformed pharmacokinetic endpoints such as AUC and C_max.

Sources recorded, not reviewed

Kilderegister

Siteringer kopiert ordrett fra metodens kilderegister. Ingen påstandsnivåverifisering er underforstått fra dem.

Bioequivalence Analysis (Two One-Sided Tests)

Taksonomisk metoderegister · hypothesis-test / pharmacometrics

Schuirmann, D. J. (1987). A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. Journal of Pharmacokinetics and Biopharmaceutics, 15(6), 657–680. · DOI 10.1007/BF01068419

Åpne full metode

Kuraterte påstander

Påstander lagret i bevishovedboken, hver med sin egen vurdering.

Ingen kuraterte påstander ennå

Denne visningen finner ikke opp en påstandsvurdering når hovedboken ikke har noen.

Relaterte metoder

Generert fra metodegrafen og vist som maskinforslåtte relasjoner – ingen bevispåstand er underforstått.

Same method familyEquivalence Test (TOST)machine-suggested · Relational suggestion, not evidence.Used in the same domainPharmacokinetic Compartment Modelmachine-suggested · Relational suggestion, not evidence.